Literature DB >> 1394142

Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients.

D P Rose1, R T Chlebowski, J M Connolly, L A Jones, E L Wynder.   

Abstract

Serum was collected at intervals from postmenopausal breast cancer patients to determine the effects of tamoxifen adjuvant therapy and a low-fat dietary intervention, alone and in combination, on sex hormone-binding globulin (SHBG) concentrations and circulating estradiol bioavailability. Serum corticosteroid-binding globulin and follicle-stimulating hormone were also assayed as indicators of patient compliance to tamoxifen therapy. The immunoreactive SHBG concentration was higher (P less than 0.001) in 22 patients who had been treated with tamoxifen for 6-36 weeks when first sampled, compared with 27 who were not receiving tamoxifen therapy. Tamoxifen also produced a reduction in the percentage non-protein-bound estradiol (P less than 0.001) and percentage albumin-bound estradiol (P less than 0.01), the two biologically available fractions, and a corresponding increase in the percentage SHBG-bound estradiol (P less than 0.01). A longitudinal study of 7 patients showed significant reductions in the percentage of albumin-bound estradiol and an increased percentage of SHBG-bound estradiol, after 3-6 months of tamoxifen; after 12-18 months there was also a significant decrease in the non-protein-bound estradiol fraction. We conclude that in postmenopausal breast cancer patients the redistribution of circulating estradiol, with reduced bioavailability, provides an additional mechanism to those demonstrated previously for the therapeutic activity of tamoxifen. Another 12 patients receiving tamoxifen and 8 who were not were followed for 6-12 months on a low-fat diet (fat comprised 20% of the total calories). The dietary intervention had no effect on the serum SHBG concentration or the estradiol distribution. Although tamoxifen increased the serum corticosteroid-binding globulin and partially suppressed the follicle-stimulating hormone concentrations, the responses obtained were less consistent compared with those of the SHBG levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394142

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Reduced or modified dietary fat for preventing cardiovascular disease.

Authors:  Lee Hooper; Carolyn D Summerbell; Rachel Thompson; Deirdre Sills; Felicia G Roberts; Helen J Moore; George Davey Smith
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Dietary fat, tamoxifen use and circulating sex hormones in postmenopausal breast cancer survivors.

Authors:  Marian L Neuhouser; Marzieh Nojomi; Richard N Baumgartner; Kathy B Baumgartner; Frank Gilliland; Leslie Bernstein; Frank Stanczyk; Rachel Ballard-Barbash; Anne McTiernan
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

3.  Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

Authors:  Hyunki Kim; Sharon L Samuel; Guihua Zhai; Samir Rana; Marie Taylor; Heidi R Umphrey; Denise K Oelschlager; Donald J Buchsbaum; Kurt R Zinn
Journal:  Cancer Biol Ther       Date:  2014-08       Impact factor: 4.742

4.  The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients.

Authors:  D P Rose; J M Connolly; R T Chlebowski; I M Buzzard; E L Wynder
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

Review 5.  Molecular mechanisms of antiestrogen action in breast cancer.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 6.  Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

Review 7.  Reduced or modified dietary fat for preventing cardiovascular disease.

Authors:  Lee Hooper; Carolyn D Summerbell; Rachel Thompson; Deirdre Sills; Felicia G Roberts; Helen Moore; George Davey Smith
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

8.  Diffusion weighted imaging evaluated the early therapy effect of tamoxifen in an MNU-induced mammary cancer rat model.

Authors:  Guihua Zhai; Clinton J Grubbs; Cecil R Stockard; Heidi R Umphrey; T Mark Beasley; Hyunki Kim
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

9.  Omega-6 fats for the primary and secondary prevention of cardiovascular disease.

Authors:  Lee Hooper; Lena Al-Khudairy; Asmaa S Abdelhamid; Karen Rees; Julii S Brainard; Tracey J Brown; Sarah M Ajabnoor; Alex T O'Brien; Lauren E Winstanley; Daisy H Donaldson; Fujian Song; Katherine Ho Deane
Journal:  Cochrane Database Syst Rev       Date:  2018-11-29

10.  Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Nicole Martin; Charlene Bridges; Julii S Brainard; Xia Wang; Tracey J Brown; Sarah Hanson; Oluseyi F Jimoh; Sarah M Ajabnoor; Katherine Ho Deane; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.